Patent application number | Description | Published |
20080247955 | Inflammation treatment, detection and monitoring via TREM-1 - The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient. | 10-09-2008 |
20080248460 | Composition and method for modulating an inflammatory response - The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided. | 10-09-2008 |
20140134176 | PLATELET-DERIVED GROWTH FACTOR B SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF - The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions. | 05-15-2014 |
Patent application number | Description | Published |
20110263726 | PROCESS FOR SELECTIVE OXIDATIVE DEHYDROGENATION OF A HYDROGEN-CONTAINING CO MIXED GAS - A process for selective oxidative dehydrogenation of a hydrogen-containing CO mixed gas, comprising contacting a hydrogen-containing CO mixed gas raw material with at least one catalyst entity having an increased activity gradient disposed in a reactor under at least one reaction condition chosen from a reaction temperature ranging from 100 to 300° C., a volume space velocity ranging from 100 to 10000 h | 10-27-2011 |
20110319684 | METHOD FOR SELECTIVE HYDROGENATION OF PHENYLACETYLENE USING COMPOSITE BED IN THE PRESENCE OF STYRENE - The present invention discloses a process for the selective hydrogenation of phenylacetylene in the presence of styrene conducted in a combined bed, which process comprises under hydrogenation reaction conditions, passing a hydrocarbon fraction feedstock containing phenylacetylene and styrene through a combined bed reactor containing a catalyst A and a catalyst B to contact the feedstock with the catalyst A and the catalyst B in turn, wherein the catalyst A is a nickel-based catalyst, the catalyst B is at least one selected from the group consisting of palladium-based catalysts and copper-based catalysts, and a weight ratio of the catalyst A loaded to the catalyst B loaded is from | 12-29-2011 |
20130197265 | PROCESS OF PRODUCING OXALATE BY CO GAS PHASE METHOD - The present invention relates to a process of producing oxalate by CO gas phase method for chiefly solving the technical problem of the low utilization efficiency of nitrogen oxides or nitrous acid esters in the prior art. The present invention solves the problem in a better way by using the following steps including: a gas phase stream V containing NO and methanol and oxygen enter a supergravity rotating bed reactor II and are subjected to the oxidative esterification reaction to produce an effluent VI containing methyl nitrite; a methyl nitrite effluent VII obtained from separating said effluent VI together with a CO gas II enter a coupling reactor II and is contacted with a catalyst II to react to form a dimethyl oxalate effluent VIII and a gas phase effluent IX containing NO; the resultant dimethyl oxalate effluent VIII is separated to obtain a dimethyl oxalate product I; optionally, the gas phase effluent IX containing NO is returned to the step above so as to be mixed with the gas phase stream V containing NO for being recycled. Therefore, the process is applicable to the industrial production of oxalate by CO gas phase method. | 08-01-2013 |
20130331617 | METHOD FOR PRODUCING ETHYLENE GLYCOL FROM OXALATE THROUGH THE FLUIDIZED BED CATALYTIC REACTION - A process for producing ethylene glycol includes contacting an oxalate with a fluidized bed catalyst under the following conditions: a reaction temperature of from about 170 to about 270° C., a weight space velocity of oxalate of from about 0.2 to about 7 hours | 12-12-2013 |